多西他赛单药一线治疗老年晚期非小细胞肺癌的临床观察  

Observation of domestic docetaxel in the first line treatment of elderly patients with advanced non-small cell lung cancer

作　　者：胡凤[1] 王强[1] 王晓红[1] 刘永刚[1] 

机构地区：[1]包头市肿瘤医院肿瘤内科,内蒙古包头014030

出　　处：《疾病监测与控制》2011年第8期465-466,共2页Journal of Diseases Monitor and Control

摘　　要：目的观察多西他赛单药一线治疗老年晚期非小细胞肺癌患者的临床疗效。方法 30例晚期非小细胞肺癌初治老年患者予以多西他赛70mg/m^2治疗,21d为1周期,完成2周期后评价疗效,有效及稳定病例治疗4个周期,随访至疾病进展和死亡。结果 26名可评价病例中,总有效率26.9%,疾病控制率57.6%,中位无进展生存期3.6个月。中位生存期8.5个月,1年生存率为35.6%,主要毒副反应为细胞减少,乏力,脱发为主,分别为61%,64%,57%。结论国产多西他赛单药一线治疗老年晚期非小细胞肺癌有效且耐受性好。Objective To observe the efficacy of domestic docetaxel in elderly patients with advanced non-small cell lung cancer（NSCLC）.Methods Twenty-eight elderly patients with advanced NSCLC who were chemotherapy-naive were treated with domestic docetaxel at the dose of 70 mg/m^2.Re-evaluation was done after two cycles.Those who did not get progressed went through another two cycles of chemotherapy and all patients were followed up until disease progressed or patients died.Results Twenty-six patients were evaluated with 26.9%response rate,57.6%stable disease,3.6 months of median progression free survival（PFS）,8.5 months of median OS and 35.6%1-year survival rate.The common adverse events were neutropenia（61%）,asthenia（64%） and alopecia（57%）.Conclusion Domestic docetaxel is effective in the first line treatment of elderly patients with advanced NSCLC and patients tolerate well.

关 键 词：多西他赛 一线治疗 老年非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]